Our research data are consistent with the abovementioned findings, confirming the collective response of PECAM-1 in endotheliocytes and macrophages, which is the theoretical basis of the targeted nanotherapeutics-based drug delivery system to improve the treatment of ALI. The gene discussed is PECAM1; the disease is acute respiratory distress syndrome.